Tag: gene

GlobeNewswire

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia AviadoBio to start clinical trials with its gene therapy candidate later this year London, UK,...
ACN Newswire

Legend Capital’s Co-founded Company Innostellar Biotherapeutics: IRD Gene Therapy Product was Approved for Clinical Trial in China

HONG KONG, Apr 24, 2022 - (ACN Newswire via SEAPRWire.com) - Shanghai Langsheng Biotechnology Co., Ltd., a subsidiary of Legend Capital's co-founded company Innostellar Biotherapeutics, announced that the clinical trial application of its product LX101 injection for the treatment of patients with Rpe65 biallelic mutation-associated inherited retinal degenerations (IRD) was...
ACN Newswire

ICCPP Holds GENE TREE Online Roundtable

SHENZHEN, CHINA, Sep 16, 2021 - (ACN Newswire via SEAPRWire.com) - At 6 p.m. on September 8 UTC+8, the GENE TREE Technology Sharing Online Roundtable with the theme of "Exploration and Innovation" was successfully held as scheduled. As the organizer of the online meeting, ICCPP, having built well-known international atomization...
JCN Newswire

Anticancer Agent “Tazverik Tablets 200mg” (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma

TOKYO, Aug 16, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not...
JCN Newswire

Anticancer Agent “Tazverik Tablets 200mg” (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma

TOKYO, Jun 23, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has obtained manufacturing and marketing approval for the EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide) in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard...
Close